KR20250026875A - Pcna 억제제 - Google Patents

Pcna 억제제 Download PDF

Info

Publication number
KR20250026875A
KR20250026875A KR1020257004433A KR20257004433A KR20250026875A KR 20250026875 A KR20250026875 A KR 20250026875A KR 1020257004433 A KR1020257004433 A KR 1020257004433A KR 20257004433 A KR20257004433 A KR 20257004433A KR 20250026875 A KR20250026875 A KR 20250026875A
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
independently
alkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257004433A
Other languages
English (en)
Korean (ko)
Inventor
린다 에이치 말커스
데이비드 혼
로버트 제이 히키
롱 구
Original Assignee
시티 오브 호프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250026875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 시티 오브 호프 filed Critical 시티 오브 호프
Publication of KR20250026875A publication Critical patent/KR20250026875A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020257004433A 2015-09-17 2016-09-16 Pcna 억제제 Pending KR20250026875A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562220014P 2015-09-17 2015-09-17
US62/220,014 2015-09-17
US201662313592P 2016-03-25 2016-03-25
US62/313,592 2016-03-25
US201662340964P 2016-05-24 2016-05-24
US62/340,964 2016-05-24
PCT/US2016/052310 WO2017049206A1 (en) 2015-09-17 2016-09-16 Pcna inhibitors
KR1020187010753A KR102768838B1 (ko) 2015-09-17 2016-09-16 Pcna 억제제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010753A Division KR102768838B1 (ko) 2015-09-17 2016-09-16 Pcna 억제제

Publications (1)

Publication Number Publication Date
KR20250026875A true KR20250026875A (ko) 2025-02-25

Family

ID=58289682

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257004433A Pending KR20250026875A (ko) 2015-09-17 2016-09-16 Pcna 억제제
KR1020187010753A Active KR102768838B1 (ko) 2015-09-17 2016-09-16 Pcna 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187010753A Active KR102768838B1 (ko) 2015-09-17 2016-09-16 Pcna 억제제

Country Status (11)

Country Link
US (5) US10550070B2 (enExample)
EP (2) EP3349754B9 (enExample)
JP (4) JP6966996B2 (enExample)
KR (2) KR20250026875A (enExample)
CN (2) CN113620833A (enExample)
AU (3) AU2016324158B2 (enExample)
CA (1) CA2999080C (enExample)
ES (1) ES3040726T3 (enExample)
IL (4) IL282400B (enExample)
MX (2) MX2021006326A (enExample)
WO (1) WO2017049206A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
CN113620833A (zh) 2015-09-17 2021-11-09 希望之城 Pcna抑制剂
US11392971B1 (en) * 2017-12-29 2022-07-19 Groupon, Inc. Methods and systems for generating a supply index indicative of a quality of available supply of merchant promotions
US11551247B1 (en) 2017-12-29 2023-01-10 Groupon, Inc. Methods and systems for determining a travel propensity configured for use in the generation of a supply index indicative of a quality of available supply
CA3217330A1 (en) * 2021-04-30 2022-11-03 City Of Hope Pcna inhibitors and egfr inhibitors for cancer treatment
IL315296A (en) * 2022-03-07 2024-10-01 Hope City Pcna inhibitors and uses thereof
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN117603081A (zh) * 2023-11-28 2024-02-27 沈阳药科大学 N-(2-((2-(3-甲氧基苯氧基)苯基)氨基)-2-乙酰氧基)-1-萘胺的制备方法
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers
CN118546074B (zh) * 2024-05-27 2025-06-06 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用
CN118459363B (zh) * 2024-05-27 2024-12-17 安徽贝克制药股份有限公司 一种氟取代增殖细胞核抗原抑制剂及其制备方法和其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1295611A (en) * 1916-07-29 1919-02-25 Moritz D Schwartz Metatarsal support.
US1298989A (en) * 1918-11-14 1919-04-01 Reed Foundry & Machine Co Tractor-plow.
US4030910A (en) * 1974-01-22 1977-06-21 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, herbicidal compositions and methods containing same
US4269829A (en) * 1979-06-18 1981-05-26 Rohm And Haas Company Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
TR200103406T2 (tr) * 1998-03-19 2002-06-21 Vertex Pharmaceuticals Incorporated Kaspaz inhibitörleri.
AU2333099A (en) * 1998-03-20 1999-10-18 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
CA2542064A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070155727A1 (en) * 2005-12-29 2007-07-05 Schering Aktiengessellschaft Amide inhibitors of leukotriene A4 hydrolase
CA2740571A1 (en) * 2008-10-17 2011-04-13 Exelixis, Inc. Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
AU2009305624A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
MX340490B (es) * 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
CN103189063B (zh) * 2010-11-01 2016-10-19 宾夕法尼亚州研究基金会 治疗组合物和方法
CN103619331A (zh) * 2011-03-23 2014-03-05 印第安纳大学研究及科技公司 抗癌治疗剂
CN106029632B (zh) * 2014-02-28 2019-06-21 国立大学法人东北大学 酰胺衍生物
CN113620833A (zh) 2015-09-17 2021-11-09 希望之城 Pcna抑制剂

Also Published As

Publication number Publication date
EP3349754C0 (en) 2025-07-16
ES3040726T3 (en) 2025-11-04
US12054447B2 (en) 2024-08-06
CN113620833A (zh) 2021-11-09
CN108348512B (zh) 2021-09-03
WO2017049206A1 (en) 2017-03-23
IL276115B (en) 2021-05-31
US20200216386A1 (en) 2020-07-09
MX2021006326A (es) 2022-12-16
IL294381A (en) 2022-08-01
AU2016324158A1 (en) 2018-04-12
EP3349754A1 (en) 2018-07-25
JP2025128193A (ja) 2025-09-02
US10913706B2 (en) 2021-02-09
EP3349754A4 (en) 2019-03-20
IL282400A (en) 2021-06-30
MX382996B (es) 2025-03-13
EP4616910A2 (en) 2025-09-17
US11345656B2 (en) 2022-05-31
US20240343682A1 (en) 2024-10-17
AU2023201501A1 (en) 2023-04-13
JP7399925B2 (ja) 2023-12-18
AU2020270487A1 (en) 2020-12-17
CN108348512A (zh) 2018-07-31
US20220340516A1 (en) 2022-10-27
IL294381B1 (en) 2023-03-01
CA2999080C (en) 2023-11-14
AU2016324158B2 (en) 2020-08-27
JP7690553B2 (ja) 2025-06-10
IL258174B (en) 2020-08-31
US20180339960A1 (en) 2018-11-29
IL282400B (en) 2022-08-01
AU2023201501B2 (en) 2024-07-04
JP2024028846A (ja) 2024-03-05
EP4616910A3 (en) 2025-11-05
CA2999080A1 (en) 2017-03-23
JP2019500315A (ja) 2019-01-10
JP6966996B2 (ja) 2021-11-17
MX2018003301A (es) 2019-02-07
NZ740817A (en) 2024-03-22
EP3349754B9 (en) 2025-10-22
AU2020270487B2 (en) 2022-12-15
IL276115A (en) 2020-08-31
KR20180069817A (ko) 2018-06-25
US10550070B2 (en) 2020-02-04
KR102768838B1 (ko) 2025-02-14
HK1258793A1 (en) 2019-11-22
BR112018005331A2 (pt) 2018-10-09
IL258174A (en) 2018-05-31
IL294381B2 (en) 2023-07-01
US20210078938A1 (en) 2021-03-18
US12435030B2 (en) 2025-10-07
EP3349754B1 (en) 2025-07-16
JP2022028665A (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
JP7690553B2 (ja) Ｐｃｎａ阻害剤
KR20240158305A (ko) Pcna 억제제 및 이의 용도
KR20240004548A (ko) 암 치료를 위한 pcna 억제제 및 egfr 억제제
CN115697331A (zh) Taspase1抑制剂及其用途
HK40055283A (en) Pcna inhibitors
HK1258659A1 (en) Pcna inhibitors
HK1258659B (en) Pcna inhibitors
EA048301B1 (ru) Ингибиторы pcna
EA040083B1 (ru) Соединения, ингибирующие pcna, фармацевтические композиции и способы лечения заболеваний, связанных с активностью pcna
HK1258793B (en) Pcna inhibitors
BR112018005331B1 (pt) Inibidores de pcna

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250211

Application number text: 1020187010753

Filing date: 20180416

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250310

Comment text: Request for Examination of Application